Vulvovaginal candidiasis (VVC) and recurrent vulvovaginal candidiasis (RVVC) are common infections in reproductive-age women, caused by the fungus Candida albicans. A recent study published in 2026 investigated how C. albicans regulates local vaginal epithelial immunity using mouse models.
The research focused on the NLRP3/IL-1β pathway, a key component of the innate immune response. The study found that C. albicans can suppress this pathway, reducing the production of interleukin-1β (IL-1β) and thereby dampening the local immune response. This mechanism may contribute to the persistence and recurrence of infection.
In the mouse models, the fungus modulated the NLRP3 inflammasome, leading to decreased IL-1β secretion from vaginal epithelial cells. This suppression of immunity allowed the infection to establish and recur, mimicking the clinical pattern of RVVC in humans.
The findings suggest that targeting the NLRP3/IL-1β pathway could offer new therapeutic strategies for treating VVC and RVVC. Further research is needed to confirm these mechanisms in human patients.
